VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, is pleased to announce that it has received a $307,000 contribution from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to develop genetic biomarkers for cardiovascular disease (CVD).

CVD accounts for the death of more Canadians and Americans than any other disease, killing each year approximately 75,000 Canadians (Canadian Heart & Stroke Foundation) and 480,000 Americans (American Heart Association).

“We believe that Med BioGene’s expertise in gene expression and the continued development and validation of our genetic signatures for CVD, coupled with access to world-class scientific knowledge and blood samples from patients with confirmed CVD through our collaboration with the University of Ottawa Heart Institute, will create an effective environment for the development of a novel tool for use in screening and in improving diagnosis, prognosis and treatment decisions for patients suffering from CVD� said Erinn Broshko, Chief Executive Officer of MBI.

“It is essential that doctors identify CVD at a very early stage – long before any symptoms become prevalent – to allow for identification of patients at risk of fatal or debilitating cardiovascular events, and early implementation of preventive strategies and treatments.  As a screening tool, MBI’s genetic biomarkers for CVD are expected to be an invaluable tool for periodic screening of patients who may be at risk for developing clinically significant CVD.  Such screening will serve as an accurate first step in diagnosing patients with early, mid or late-stage CVD.  If a patient is found to have significant CVD, their cardiologist can then perform further testing in these patients, thereby directing expensive and limited testing towards those who need it the most, and sparing patients not at risk from unnecessary and invasive testing�, noted Dr. T. Nathan Yoganathan, President and Chief Scientific Officer of MBI.

“We are very pleased that NRC-IRAP has chosen to support such important research and development and we look forward to working closely with them throughout the project� concluded Mr. Broshko.

About NRC-IRAP

NRC-IRAP is Canada's premier innovation assistance program for small and medium-sized enterprises (“SMEs�).  It is a vital component of the National Research Council Canada, a cornerstone in Canada's innovation system, regarded world-wide as one of the best programs of its kind.  NRC-IRAP's mandate — to stimulate wealth creation for Canada through technological innovation — is largely accomplished by providing technology assistance to SMEs at all stages of the innovation process, to build their innovation capacity.

NRC-IRAP helps SMEs understand the technology issues and opportunities and provides linkages to the best expertise in Canada.  NRC-IRAP provides a range of both technical and business oriented advisory services along with potential financial support to SMEs. The program is delivered by an extensive integrated network of 260 professionals in 100 communities across Canada.  Working directly with SMEs, NRC-IRAP supports innovative research and development and commercialization of new products and services.

About Med BioGene

MBI is a biotechnology company with advanced research and development in gene expression technology. MBI intends to utilize its expertise in gene expression to identifying those genes, known as "biomarkers," which mark the presence of various diseases. These biomarkers will be used as an effective tool for accurate and rapid disease diagnosis and to unlock innovation in therapeutic development and treatment. With a robust set of qualified biomarkers, disease diagnosis will be quicker, less invasive and more accurate and the safety of new therapeutics will be increased, drug products will get to patients in less time and treatment decisions will be more informed.

MBI is currently focused on developing and validating biomarkers in respect of lymphoma, leukemia and cardiovascular disease through its Gene Expression Profiling SystemTM.

For further information, please contact:

Erinn B. Broshko
Chief Executive Officer
(604) 306-4969
ebroshko@medbiogene.com
www.medbiogene.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation.  Words such as “anticipates,� “believes,� “estimates,� “expects,� “intends,� “may,� “plans,� “projects,� “will,� “would� and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but are not limited to, those with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements or information are only predictions based upon MBI’s current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI’s actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. Our forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.